
Antti Tanskanen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4213008/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11) Tj ETQq1	0.784314	· rgBT /Ove
2	Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29†823 Patients With Schizophrenia. JAMA Psychiatry, 2017, 74, 686.	11.0	460
3	20â€year followâ€up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry, 2020, 19, 61-68.	10.4	232
4	Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study. American Journal of Psychiatry, 2016, 173, 600-606.	7.2	160
5	From prescription drug purchases to drug use periods – a second generation method (PRE2DUP). BMC Medical Informatics and Decision Making, 2015, 15, 21.	3.0	137
6	20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia. American Journal of Psychiatry, 2018, 175, 765-773.	7.2	134
7	Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. JAMA Psychiatry, 2018, 75, 347.	11.0	116
8	Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study. BMJ Open, 2016, 6, e012100.	1.9	75
9	No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease. American Journal of Gastroenterology, 2017, 112, 1802-1808.	0.4	69
10	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. Neuroscience and Biobehavioral Reviews, 2022, 136, 104608.	6.1	67
11	Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons. Clinical Epidemiology, 2016, Volume 8, 363-371.	3.0	61
12	Metformin and Risk of Alzheimer's Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e963-e972.	3.6	60
13	Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry,the, 2021, 8, 883-891.	7.4	50
14	Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials. JAMA Psychiatry, 2022, 79, 210.	11.0	47
15	Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research – the Medication use among persons with Alzheimer's disease (MEDALZ-2005) study. Clinical Epidemiology, 2013, 5, 277.	3.0	43
16	Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer's disease – exposure-matched cohort study. BMC Geriatrics, 2016, 16, 204.	2.7	43
17	Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia. NPJ Schizophrenia, 2021, 7, 1.	3.6	40
18	Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Lancet Psychiatry,the, 2017, 4, 547-553.	7.4	39

ANTTI TANSKANEN

#	Article	IF	CITATIONS
19	Research Priorities for Optimizing Geriatric Pharmacotherapy: An International Consensus. Journal of the American Medical Directors Association, 2018, 19, 193-199.	2.5	35
20	Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia. Schizophrenia Bulletin, 2021, 47, 23-30.	4.3	35
21	Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. Schizophrenia Bulletin, 2021, 47, 1611-1620.	4.3	33
22	Drug exposure in register-based research—An expert-opinion based evaluation of methods. PLoS ONE, 2017, 12, e0184070.	2.5	31
23	Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychological Medicine, 2020, 50, 1356-1367.	4.5	26
24	Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. Schizophrenia Bulletin, 2022, 48, 166-175.	4.3	26
25	Morbidity and mortality in schizophrenia with comorbid substance use disorders. Acta Psychiatrica Scandinavica, 2021, 144, 42-49.	4.5	25
26	Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 107-118.	2.6	24
27	Comparison of dispensed medications and forensicâ€ŧoxicological findings to assess pharmacotherapy in the Swedish population 2006 to 2013. Pharmacoepidemiology and Drug Safety, 2018, 27, 1112-1122.	1.9	24
28	Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland. JAMA Network Open, 2020, 3, e2019029.	5.9	24
29	Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. Schizophrenia Bulletin, 2021, 47, 1621-1630.	4.3	24
30	Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer's Disease. Journal of Clinical Psychiatry, 2017, 78, e257-e263.	2.2	23
31	Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study. Pain, 2019, 160, 417-423.	4.2	20
32	Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort study. Journal of Affective Disorders, 2020, 277, 885-892.	4.1	20
33	Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia. Schizophrenia Bulletin, 2022, 48, 655-663.	4.3	19
34	Antipsychotic Doses Among Community-Dwelling Persons With Alzheimer Disease in Finland. Journal of Clinical Psychopharmacology, 2014, 34, 435-440.	1.4	18
35	Realâ€world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nationâ€wide cohort of 125 556 patients. Addiction, 2021, 116, 1990-1998.	3.3	16
36	Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences. Nordic Journal of Psychiatry, 2021, 75, 315-322.	1.3	15

Antti Tanskanen

#	Article	IF	CITATIONS
37	Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. Lancet Psychiatry,the, 2022, 9, 353-362.	7.4	15
38	Drug use in persons with and without Alzheimer's disease aged 90 years or more. Age and Ageing, 2016, 45, 900-904.	1.6	14
39	Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia. European Journal of Clinical Pharmacology, 2020, 76, 711-718.	1.9	13
40	From prescriptions to drug use periods - things to notice. BMC Research Notes, 2014, 7, 796.	1.4	12
41	Incidence and Prevalence of Antiepileptic Medication Use in Community-Dwelling Persons with and without Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 66, 387-395.	2.6	11
42	Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease. Neurology, 2020, 94, e2099-e2108.	1.1	10
43	Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder. Schizophrenia Bulletin, 2021, 47, 1099-1107.	4.3	10
44	Effectiveness of pharmacotherapies for delusional disorder in a Swedish national cohort of 9076 patients. Schizophrenia Research, 2021, 228, 367-372.	2.0	10
45	Month and Season of Birth as a Risk Factor for Alzheimer's Disease: A Nationwide Nested Case-control Study. Journal of Preventive Medicine and Public Health, 2016, 49, 134-138.	1.9	9
46	Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. Schizophrenia Bulletin, 2022, 48, 774-784.	4.3	9
47	Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's disease. European Journal of Clinical Pharmacology, 2019, 75, 417-425.	1.9	8
48	Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia. Medical Care, 2020, 58, 763-769.	2.4	8
49	Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study. Journal of Affective Disorders, 2022, 308, 236-242.	4.1	8
50	Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer's disease: a nationwide matched cohort study. Alzheimer's Research and Therapy, 2017, 9, 59.	6.2	7
51	Hospital-Treated Pneumonia Associated with Opioid Use Among Community Dwellers with Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 807-816.	2.6	7
52	Concomitant use of benzodiazepines and opioids in communityâ€dwelling older people with or without Alzheimer's disease—A nationwide registerâ€based study in <scp>Finland</scp> . International Journal of Geriatric Psychiatry, 2019, 34, 280-288.	2.7	6
53	Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease. Journal of the American Medical Directors Association, 2019, 20, 1488-1494.e3.	2.5	5
54	Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases. Acta Psychiatrica Scandinavica, 2021, 143, 487-494.	4.5	5

Antti Tanskanen

#	Article	IF	CITATIONS
55	Does Recent Hospitalization Increase Antipsychotic Initiation Among Community Dwellers With Alzheimer's Disease?. Journal of the American Medical Directors Association, 2021, 22, 1543-1547.e3.	2.5	5
56	Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer's disease in 2005-2011. PLoS ONE, 2017, 12, e0173450.	2.5	5
57	Realâ€world effectiveness of pharmacological treatments of opioid use disorder in a national cohort. Addiction, 2022, 117, 1683-1691.	3.3	5
58	Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer's Disease. Journal of the American Medical Directors Association, 2019, 20, 751-758.	2.5	4
59	Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease. International Journal of Cardiology, 2020, 300, 221-225.	1.7	4
60	Persistence of antidepressant use among refugee youth with common mental disorder. Journal of Affective Disorders, 2021, 294, 831-837.	4.1	4
61	Antidepressant use among immigrants with depressive disorder living in Finland: A register-based study. Journal of Affective Disorders, 2022, 299, 528-535.	4.1	4
62	Screening approach for identifying candidate drugs and drugâ€drug interactions related to hip fracture risk in persons with Alzheimer disease. Pharmacoepidemiology and Drug Safety, 2017, 26, 875-889.	1.9	3
63	Systemic Estrogen Use and Discontinuation After Alzheimer's Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study. Drugs and Aging, 2018, 35, 985-992.	2.7	3
64	Switches and early discontinuations of antidepressant medication in young adults with depression. Journal of Affective Disorders, 2021, 295, 1474-1481.	4.1	3
65	Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer's Disease. Clinical Epidemiology, 2021, Volume 13, 295-307.	3.0	2
66	Changes in the use of diabetes drugs among community-dwelling people with Alzheimer's disease. BMC Geriatrics, 2021, 21, 701.	2.7	2
67	Prevalence of oral anticoagulant use among people with and without Alzheimer's disease. BMC Geriatrics, 2022, 22, .	2.7	2
68	Continuity of antipsychotic medication use among migrant and Finnish-born populations with a psychotic disorder: a register-based study. Psychological Medicine, 2023, 53, 833-843.	4.5	1
69	Automated multi-dose dispensing in persons with and without Alzheimer's disease—impacts on pharmacotherapy. European Journal of Clinical Pharmacology, 2022, 78, 513-521.	1.9	Ο